Epidermolysis Bullosa
Epidermolysis Bullosa (EB) is a group of rare genetic skin disorders that cause the skin to be very fragile and blister easily, often from minor injuries or friction.
Deucravacitinib for Inflammatory Skin Conditions
We are studying a new treatment for adults with inflammatory epidermal genodermatoses, including severe forms of ichthyosis and epidermolysis bullosa. The trial will evaluate how well it works and its safety over time.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Congenital Ichthyosis
Congenital Ichthyosis is a genetic skin disorder characterized by dry, scaly skin that can appear thick and may lead to complications such as infections.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you over 18 years old?
- Do you have a confirmed diagnosis of Epidermolysis Bullosa Simplex (EBS)?
- Have you used systemic immunotherapy or chemotherapy in the last 60 days?
- Have you used systemic steroid therapy in the last 30 days?
- Have you used any diacerein-containing products in the last 6 months?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Centre Hospitalier Universitaire De Nice
Dermatologie
Nice, France
Assistance Publique Hopitaux De Paris
Dermatology
Quinze-Vingts, France
Sponsor: Centre Hospitalier Universitaire De Nice
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.